GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsTheclinical comparative study met its primary endpoint and showed similar efficacyand comparable safety profile in patients with moderate to severe plaque psoriasisGUANGZHOU,China, November 29, 2023 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177:S...
GUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) publish...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA.TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United StatesTOFIDENCE is the first biosi...
